A5072104235- Diabetes Treatment and Management
- Potassium and Related Disorders
- Electrolyte and hormonal disorders
- Pharmacology and Obesity Treatment
- Nitric Oxide and Endothelin Effects
- Pancreatic function and diabetes
- Neuroinflammation and Neurodegeneration Mechanisms
- Alzheimer's disease research and treatments
- Blood Pressure and Hypertension Studies
- Cardiovascular Function and Risk Factors
- Bipolar Disorder and Treatment
- Heart Failure Treatment and Management
- Diabetes Management and Research
- Dementia and Cognitive Impairment Research
- Apelin-related biomedical research
- Ion Transport and Channel Regulation
- Hormonal Regulation and Hypertension
Aarhus University Hospital
2017-2024
Aarhus University
2022-2024
See Kreisl (doi:10.1093/awx151) for a scientific commentary on this article.Subjects with mild cognitive impairment associated cortical amyloid-β have greatly increased risk of progressing to Alzheimer's disease. We hypothesized that neuroinflammation occurs early in disease and would be present most amyloid-positive cases. 11C-Pittsburgh compound B 11C-(R)-PK11195 positron emission tomography was used determine the amyloid load detect extent (microglial activation) 42 Twelve age-matched...
ABSTRACT Background Dapagliflozin and finerenone reduce albuminuria slow CKD progression, but additive effects remain unstudied. We compared their individual combined efficacy safety in patients with non-diabetic CKD. Methods In an open-label, randomized clinical trial, we included aged 18–80 on maximal tolerated ACE inhibitor or angiotensin receptor blocker eGFR 25–45 mL/min/1,73 m2 150–2000 mg/g. Participants received either 20 mg/day dapagliflozin 10 for four weeks, followed by...
Chronic kidney disease (CKD) is associated with significantly increased morbidity and mortality. No specific treatment of the underlying condition available for majority patients, but ACE-inhibitors (ACE-I) angiotensin II-receptor blockers (ARB) slows progression in albuminuric CKD. Adding a mineralocorticoid receptor-antagonist (MRA) like spironolactone has an additive effect. However, renin-angiotensin-aldosterone system (RAAS)-blockade increases risk hyperkalaemia which exacerbated by...
Abstract Aims The objective of this study was to examine the effects empagliflozin on endothelium‐dependent and endothelium‐independent vasodilatation systemic hemodynamic parameters assess role nitric oxide (NO) system in patients with type 2 diabetes (T2DM). Materials Methods In double‐blind, placebo‐controlled cross over trial, T2DM were treated either 10 mg or matching placebo for 4 weeks. Following a 2‐week washout, participants crossed weeks opposite treatment. Forearm blood flow (FBF)...
We tested the feasibility of adding a potassium binder to enable increased renin angiotensin aldosterone system inhibition (RAASi) and reduce albuminuria in patients with chronic kidney disease (CKD). In controlled trial design, was introduced exclusively developing hyperkalemia after intensified RAASi, thereby mirroring clinical decision-making.
Abstract Background and Aims Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular events protects kidney function in type diabetes (DM2) patients. These benefits may partly be related to improvement of vascular function. In this study we examined the effects SGLT2i treatment on vasodilatory capacity patients with DM2. Method Using a double-blind, randomized, placebo-controlled cross-over design, included 15 DM2 preserved (eGFR > 60 ml/min/1.73 m2). Each participant...
Abstract Background and Aims Mineralocorticoid receptor antagonists (MRA) reduce blood pressure, albuminuria the rate of disease progression in patients with chronic kidney (CKD) albuminuria. Despite these apparent benefits, only a very small fraction CKD are treated an MRA. This may part be due to fear hyperkalemia (HK), which most severe cases can cause life-threatening arrythmias. Indeed, international guidelines previous studies have excluded believed at high risk HK from treatment MRA...